Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00667225 · ClinicalTrials.gov registry record · NA

Efficacy of Cantharidin in Molluscum Contagiosum

A NA study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
NA
Development phase
29
Enrollment target

NCT00667225 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 29 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00667225, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target

Study Summary

The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on the skin. It goes away on its own, though can last several months to several years. Cantharidin is a topical medicine which is applied at the clinic visit. It is well tolerated by the majority of children.

Interventions

  • DRUG cantharidin's vehicle
  • DRUG Cantharidin 0.7%

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2008-01
Est. Completion 2009-06
Phase NA

What the Registry Record Tells You About NCT00667225

The ClinicalTrials.gov registry entry for NCT00667225 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which cantharidin's vehicle is the first listed.

NCT00667225 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00667225 about?

NCT00667225 is a clinical study titled "Efficacy of Cantharidin in Molluscum Contagiosum". The University of North Carolina Department of Dermatology is conducting a clinical trial to evaluate a drug called cantharidin in the treatment of molluscum contagiosum. Molluscum is a common dermatologic disorder caused by a poxvirus. Molluscum typically presents with many flesh-colored bumps on t...

What is the current status of trial NCT00667225?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2008-01. Estimated completion is 2009-06.

What interventions are being tested in trial NCT00667225?

The interventions under investigation include: cantharidin's vehicle (DRUG), Cantharidin 0.7% (DRUG).

Who is sponsoring clinical trial NCT00667225?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.